Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

 In accordance with the applicable requirements and regulations of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable Regulations, we hereby inform you that the Audio Recording of the Earnings Conference Call in connection with the Unaudited Consolidated and Standalone Financial Results of the Company for the quarter and half year ended September 30, 2023, held on 08 November, 2023, is available on the website of the Company and can be accessed through the following link: Link: https://eris.co.in/financials/
08-11-2023
Bigul

Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Press Release
08-11-2023
Bigul

Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Investor Presentation

 Investor Presentation
08-11-2023
Bigul

Eris Lifesciences Ltd - 540596 - INTIMATION UNDER REGULATION 30 AND OTHER APPLICABLE REGULATIONS OF SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

 Intimation under Regulation 30 of SEBI LODR
08-11-2023
Bigul

Eris Lifesciences Ltd - 540596 - Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended September 30, 2023

 Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2023.
08-11-2023
Bigul

Eris Lifesciences Ltd - 540596 - Board Meeting Outcome for Consideration And Approval Of The Limited Reviewed Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended September 30, 2023.

 Dear Sir/Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ('LODR') we hereby inform you that the Board of Directors of the Company, in their meeting held today, i.e., November 08, 2023, inter alia, duly approved and took on record the limited reviewed Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2023. The standalone and consolidated unaudited financial results for the quarter and half year ended September 30, 2023 are enclosed. The meeting of the Board of Directors commenced at 10:30 A.M. and concluded at 02:10 P.M. This is for your information and record.
08-11-2023
Bigul

Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 INTIMATION OF SCHEDULE OF ANALYST & INVESTOR CALL PURSUANT TO REGULATION 30 AND OTHER APPLICABLE REGULATIONS OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 ('SEBI (LODR) Regulations, 2015')
01-11-2023
Bigul

Eris Lifesciences Ltd - 540596 - Board Meeting Intimation for Consideration And Approval Of Standalone And Consolidated Unaudited Financial Results Of The Company For The Quarter And Half Year Ended September 30, 2023

 Eris Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/11/2023 ,inter alia, to consider and approve the standalone and consolidated unaudited financial results of the Company for the quarter and half year ended September 30, 2023
01-11-2023
Bigul

Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Analyst / Investor meet intimation
13-10-2023
Bigul

Eris Lifesciences Ltd - 540596 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018
12-10-2023
Next Page
Close

Let's Open Free Demat Account